3M and Vaxlnnate pal up for pandemic patch

By Gareth Macdonald

- Last updated on GMT

Related tags: Influenza, Flu vaccine

3M’s drug delivery division and US biotechnology firm VaxInnate have teamed up to develop transdermal influenza vaccine delivery patch in preparation for the anticipated pandemic.

The non-exclusive license agreement allows VaxInnate to employ 3M’s patented microneedle technology, the microstructured transdermal system (MTS), in the delivery of its M2e universal flu vaccine via a skin patch.

As 3M’s MTS manager Kris Hansen explained, the project has the potential to dramatically improve the delivery of vaccines. He said that the “technology combines the ease, convenience and self-administration potential of a transdermal patch with the speed and efficiency of a traditional injection​”

He added that: "Studies using model vaccines have validated the potential effectiveness of delivering vaccines with the solid Microstructured Transdermal System​."

Mark Tomai who heads up 3M’s head of vaccine business development division added that the MTS technology’s reduced need cold-chain storage would provide significant logistical advantages in the event of a pandemic.

These thoughts were echoed by VaxInnate CEO Alan Shaw, who commented that: "The ability to deliver VaxInnate's M2e universal flu vaccine using 3M's transdermal patch could make it possible to vaccinate people rapidly for seasonal flu or in the event of a pandemic flu, when doing so is critical to stopping the spread of disease​.“

Universal vaccine for influenza

VaxInnate’s product, which is due to enter large scale clinical trials early next year, is designed to be a universal vaccine that can protect against any influenza virus. The vaccine targets the M2 ectodomain (M2e) portion of the virus, which is present in exactly the same form regardless of strain.

To date, VaxInnate has reported impressive results from early human testing indicating that the agent is highly immunogenic and protects against a very broad spectrum of influenza strains.

The New Jersey-headquartered firm believes that such an approach could eventually make seasonal influenza vaccinations redundant. An effective universal vaccine would remove the need to reformulate each winter to combat the virus strain circulating that particular season.

Additionally, such a product would have distinct advantages for health care agencies preparing for a global epidemic as it would allow them to stockpile treatments in advance, regardless of which pandemic strain emerges.

Related topics: Drug Delivery, Delivery technologies

Related news

Show more

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Local lab Data Management

Local lab Data Management

Q² Solutions | 01-May-2020 | Data Sheet

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Related suppliers

Follow us

Products

View more

Webinars